A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC

NCT03511963 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

677

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Colorectal Cancer (mCRC)

Interventions

DRUG: HLX04 100 mg in 4 ml Injection
DRUG: Avastin 100 mg in 4 ml Injection

Sponsor

Shanghai Henlius Biotech